secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001683168-24-008464
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma stockholders approve reverse split (1:2 to 1:50) and warrant repricing
--------------------------------------------------------------------------------

- Reverse split authorized at ratio between 1-for-2 and 1-for-50; passed with 7,873,677 votes for, 3,121,776 against, 314,908 abstain.
- Warrant repricing approved: new exercise price lower of $1.13 per share or closing price on approval date; 1,458,915 for, 1,106,009 against, 171,894 abstain.
- Adjournment authorization passed: 8,022,415 for, 2,904,712 against, 383,234 abstain.
- Meeting held Nov 26, 2024; quorum of 11,310,361 shares (33.82% of 33,446,403 outstanding) present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824008464/0001683168-24-008464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824008464/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-008464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer